GE HealthCare Technologies Reports Tariff Impact

By Chris Stiles • Wednesday, February 04 12:05 • Permanent Link

GE HealthCare Technologies Inc. has recently released its 10-K report, providing an in-depth look at its financial performance and operations. The company, headquartered in Chicago, Illinois, is engaged in the development, manufacture, and marketing of products, services, and digital solutions used in the diagnosis, treatment, and monitoring of patients globally. It operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx).

In the 10-K report, GE HealthCare Technologies Inc. discussed the trends and factors impacting its performance. The company highlighted the impact of global trade and the macroeconomic environment, particularly the imposition of tariffs by the U.S. and retaliatory measures by other countries. These tariffs had a material impact on the company's operating income and cash flows in 2025. GE HealthCare Technologies Inc. also addressed the potential effects of geopolitical conflicts, including the Russia-Ukraine conflict, and monitored developments closely.

In terms of financial performance, the company reported total revenues of $20,625 million for the year ended December 31, 2025, representing a 4.8% increase compared to the previous year. The revenue growth was primarily driven by strong performances in the Imaging, AVS, and PDx segments. However, the PCS segment experienced a slight decline in revenues.

The segment revenues for 2025 were as follows: Imaging segment revenues: $9,245 million, growing 4.4% AVS segment revenues: $5,354 million, growing 4.3% PCS segment revenues: $3,086 million, decreasing 1.2% PDx segment revenues: $2,900 million, growing 15.6%

In terms of regional revenues, the company experienced growth in the United States and Canada (USCAN) and Europe, the Middle East, and Africa (EMEA) regions, while facing challenges in the China market. Following these announcements, the company's shares moved -0.92%, and are now trading at a price of $81.75. If you want to know more, read the company's complete 10-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.